News
05-31-2011, 06:31 AM
BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
More... (http://www.news-medical.net/news/20110531/Enrollment-complete-in-BioSantes-LibiGel-Phase-III-cardiovascular-and-breast-cancer-safety-study.aspx)
More... (http://www.news-medical.net/news/20110531/Enrollment-complete-in-BioSantes-LibiGel-Phase-III-cardiovascular-and-breast-cancer-safety-study.aspx)